# A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis

> **NCT06586112** · PHASE3 · COMPLETED · sponsor: **Alumis Inc** · enrollment: 912 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Envudeucitinib
- **DRUG:** Apremilast
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06586112
- **Lead sponsor:** Alumis Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-25
- **Primary completion:** 2025-09-19
- **Final completion:** 2025-11-20
- **Target enrollment:** 912 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06586112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06586112, "A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06586112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*